It's easy to see why EpiPen has become the focus of America's fury over drug prices. It treats potentially deadly allergic reactions — for example, in a child who is stung by a bee — and its price has spiked by over 500% in a few years.
While it's easy to jump all over drugmakers, like EpiPen's maker, Mylan, other actors in the healthcare system ought to draw as much scrutiny.
One group of companies, called pharmaceutical-benefit managers, or PBMs, serve as middlemen, and they touch every part of the purchase of a prescription drug.
More
DelMarVa's Premier Source for News, Opinion, Analysis, and Human Interest Contact Publisher Joe Albero at alberobutzo@wmconnect.com or 410-430-5349
3 comments:
They should save their advertising money that is being used to recruit more addicts.
Actually, this is one those rare times that the government should step in and ban this type of advertising like they did with cigarettes!
I'm not sure what has been the downward turn in our healthcare, PBM's or Obamacare
Most have ties to the Clinton Foundation.
Post a Comment